Diffuse large B cell lymphoma - Pipeline Insight, 2021
![](/report_cover/8047/diffuse-large-b-cell-lymphoma-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Diffuse large B cell lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Diffuse large B cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diffuse large B cell lymphoma: Overview
Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females. Most people with DLBCL first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, DLBCL can develop in lymph nodes deep inside your body where they can’t be felt from the outside. The swollen nodes can form large lumps – known as ‘bulky disease’. DLBCL can also develop outside lymph nodes, called ‘extranodal’ disease. This affects around 1 in 5 people with DLBCL.
'Diffuse large B cell lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse large B cell lymphoma pipeline landscape is provided which includes the disease overview and Diffuse large B cell lymphoma treatment guidelines. The assessment part of the report embraces, in depth Diffuse large B cell lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse large B cell lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diffuse large B cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse large B cell lymphoma Emerging Drugs
Further product details are provided in the report..
Diffuse large B cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse large B cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Diffuse large B cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse large B cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse large B cell lymphoma drugs.
Diffuse large B cell lymphoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Diffuse large B cell lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Diffuse large B cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diffuse large B cell lymphoma: Overview
Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females. Most people with DLBCL first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, DLBCL can develop in lymph nodes deep inside your body where they can’t be felt from the outside. The swollen nodes can form large lumps – known as ‘bulky disease’. DLBCL can also develop outside lymph nodes, called ‘extranodal’ disease. This affects around 1 in 5 people with DLBCL.
'Diffuse large B cell lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse large B cell lymphoma pipeline landscape is provided which includes the disease overview and Diffuse large B cell lymphoma treatment guidelines. The assessment part of the report embraces, in depth Diffuse large B cell lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse large B cell lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse large B cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse large B cell lymphoma.
This segment of the Diffuse large B cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse large B cell lymphoma Emerging Drugs
- Epcoritamab: Genmab
- Glofitamab: Roche
- Acalabrutinib: Acerta Pharma
- AUTO 3: Autolus
- Abexinostat: Xynomic Pharmaceuticals
Further product details are provided in the report..
Diffuse large B cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse large B cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diffuse large B cell lymphoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Diffuse large B cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse large B cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse large B cell lymphoma drugs.
Diffuse large B cell lymphoma Report Insights
- Diffuse large B cell lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diffuse large B cell lymphoma drugs?
- How many Diffuse large B cell lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse large B cell lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse large B cell lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diffuse large B cell lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genmab
- Roche
- Acerta Pharma
- Autolus
- Xynomic Pharmaceuticals
- Genentech
- Celgene
- AbbVie
- Mabion
- Pharmacyclics LLC.
- Shanghai Yingli Pharmaceutical
- Philogen
- Amgen
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- JW Therapeutics
- Incyte Corporation
- BeiGene
- Miltenyi Biotec GmbH
- Beijing InnoCare Pharma Tech Co., Ltd.
- Bristol-Myers Squibb
- Celleron Therapeutics
- Otsuka Pharmaceutical
- Curis, Inc.
- Bayer
- Kartos Therapeutics, Inc.
- Shanghai Institute Of Biological Products
- Novartis Pharmaceuticals
- Constellation Pharmaceuticals
- Secura Bio, Inc.
- CytomX Therapeutics
- Juno Therapeutics
- Teneobio, Inc.
- Telios Pharma, Inc.
- Sorrento Therapeutics, Inc.
- Curocell Inc.
- TG Therapeutics, Inc.
- Tessa Therapeutics
- TCR2 Therapeutics
- Plexxikon
- Shattuck Labs, Inc.
- MEI Pharma, Inc.
- Boryung Pharmaceutical Co., Ltd
- Sutro Biopharma, Inc
- Newave Pharmaceutical Inc
- Eden BioCell Ltd.
- Adicet Bio, Inc
- VelosBio Inc.
- Seagen Inc.
- Eisai Co Ltd
- Nurix Therapeutics, Inc.
- Prelude Therapeutics
- Xencor
- Epcoritamab
- Glofitamab
- Acalabrutinib
- AUTO 3
- Abexinostat
- Atezolizumab
- Durvalumab
- Venetoclax
- MabionCD20
- Ibrutinib
- YY-20394
- Mosunetuzumab
- L19-IL2 fusion protein
- Blinatumomab
- Anlotinib Hydrochloride
- JWCAR029
- TQ-B3525
- INCB053914
- Zanubrutinib
- MB-CART2019.1
- ICP-022
- Ipilimumab
- Nivolumab
- CXD101
- OPB-111077
- CUDC-907
- Copanlisib
- KRT-232
- SIBP-02
- VAY736
- CPI-0209
- Duvelisib
- CX-2029
- CC-97540
- TNB-486
- TL-895
- STI-3031
- Ublituximab
- CRC01
- CD30.CAR-T
- TC-110 T Cells
- PLX2853
- SL-279252
- ME-401
- BR101801
- STRO-001
- LP-168
- RPM CD19-mbIL15-CAR-T cells
- ADI-001
- VLS-101
- SEA-TGT
- Tazemetostat
- NX-2127
- PRT543
- XmAb13676
Introduction
Executive Summary
Diffuse large B cell lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diffuse large B cell lymphoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diffuse large B cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diffuse large B cell lymphoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Epcoritamab: Genmab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Abexinostat: Xynomic Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
AUTO 3: Autolus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Diffuse large B cell lymphoma Key Companies
Diffuse large B cell lymphoma Key Products
Diffuse large B cell lymphoma- Unmet Needs
Diffuse large B cell lymphoma- Market Drivers and Barriers
Diffuse large B cell lymphoma- Future Perspectives and Conclusion
Diffuse large B cell lymphoma Analyst Views
Diffuse large B cell lymphoma Key Companies
Appendix
Executive Summary
Diffuse large B cell lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diffuse large B cell lymphoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diffuse large B cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diffuse large B cell lymphoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Epcoritamab: Genmab
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Abexinostat: Xynomic Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
AUTO 3: Autolus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Diffuse large B cell lymphoma Key Companies
Diffuse large B cell lymphoma Key Products
Diffuse large B cell lymphoma- Unmet Needs
Diffuse large B cell lymphoma- Market Drivers and Barriers
Diffuse large B cell lymphoma- Future Perspectives and Conclusion
Diffuse large B cell lymphoma Analyst Views
Diffuse large B cell lymphoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Diffuse large B cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Diffuse large B cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Diffuse large B cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Diffuse large B cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products